SE0104423D0 - Pregnane steroids and their use in the treatment of CNS disorders - Google Patents

Pregnane steroids and their use in the treatment of CNS disorders

Info

Publication number
SE0104423D0
SE0104423D0 SE0104423A SE0104423A SE0104423D0 SE 0104423 D0 SE0104423 D0 SE 0104423D0 SE 0104423 A SE0104423 A SE 0104423A SE 0104423 A SE0104423 A SE 0104423A SE 0104423 D0 SE0104423 D0 SE 0104423D0
Authority
SE
Sweden
Prior art keywords
treatment
cns disorders
steroid
substances
hydroxy
Prior art date
Application number
SE0104423A
Other languages
English (en)
Swedish (sv)
Inventor
Torbjoern Baeckstroem
Per Lundgren
Ming-De Wang
Original Assignee
Umecrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab filed Critical Umecrine Ab
Priority to SE0104423A priority Critical patent/SE0104423D0/xx
Publication of SE0104423D0 publication Critical patent/SE0104423D0/xx
Priority to CNB028262751A priority patent/CN100518741C/zh
Priority to CNA2009101459540A priority patent/CN101601675A/zh
Priority to CNA2009101459536A priority patent/CN101601674A/zh
Priority to ES02793723T priority patent/ES2394639T3/es
Priority to CA2468248A priority patent/CA2468248C/en
Priority to DK02793723.4T priority patent/DK1458399T3/da
Priority to EP10183670.8A priority patent/EP2275109B1/en
Priority to AU2002359202A priority patent/AU2002359202C1/en
Priority to PCT/SE2002/002423 priority patent/WO2003059357A1/en
Priority to JP2003559519A priority patent/JP2005519893A/ja
Priority to EP02793723A priority patent/EP1458399B1/en
Priority to US10/499,214 priority patent/US7960367B2/en
Priority to AU2009201956A priority patent/AU2009201956B2/en
Priority to AU2009201951A priority patent/AU2009201951A1/en
Priority to JP2009256620A priority patent/JP5289281B2/ja
Priority to US12/986,937 priority patent/US8119619B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0104423A 2001-12-27 2001-12-27 Pregnane steroids and their use in the treatment of CNS disorders SE0104423D0 (sv)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE0104423A SE0104423D0 (sv) 2001-12-27 2001-12-27 Pregnane steroids and their use in the treatment of CNS disorders
US10/499,214 US7960367B2 (en) 2001-12-27 2002-12-20 Pregnane steroids and their use in the treatment of CNS disorders
DK02793723.4T DK1458399T3 (da) 2001-12-27 2002-12-20 Pregnansteroider til brug i behandlingen af CNS-sygdomme
AU2002359202A AU2002359202C1 (en) 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of CNS disorders
CNA2009101459536A CN101601674A (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇
ES02793723T ES2394639T3 (es) 2001-12-27 2002-12-20 Esteroides de pregnano para utilización en el tratamiento de trastornos del CNS
CA2468248A CA2468248C (en) 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of cns disorders
CNB028262751A CN100518741C (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇
EP10183670.8A EP2275109B1 (en) 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of CNS disorders
CNA2009101459540A CN101601675A (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇
PCT/SE2002/002423 WO2003059357A1 (en) 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of cns disorders
JP2003559519A JP2005519893A (ja) 2001-12-27 2002-12-20 Cns疾患の治療において使用するためのプレグナンステロイド
EP02793723A EP1458399B1 (en) 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of cns disorders
AU2009201951A AU2009201951A1 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders
AU2009201956A AU2009201956B2 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders
JP2009256620A JP5289281B2 (ja) 2001-12-27 2009-11-10 Cns疾患の治療において使用するためのプレグナンステロイド
US12/986,937 US8119619B2 (en) 2001-12-27 2011-01-07 Pregnane steroids and their use in the treatment of CNS disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104423A SE0104423D0 (sv) 2001-12-27 2001-12-27 Pregnane steroids and their use in the treatment of CNS disorders

Publications (1)

Publication Number Publication Date
SE0104423D0 true SE0104423D0 (sv) 2001-12-27

Family

ID=20286518

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104423A SE0104423D0 (sv) 2001-12-27 2001-12-27 Pregnane steroids and their use in the treatment of CNS disorders

Country Status (10)

Country Link
US (2) US7960367B2 (cg-RX-API-DMAC7.html)
EP (2) EP2275109B1 (cg-RX-API-DMAC7.html)
JP (2) JP2005519893A (cg-RX-API-DMAC7.html)
CN (3) CN101601674A (cg-RX-API-DMAC7.html)
AU (3) AU2002359202C1 (cg-RX-API-DMAC7.html)
CA (1) CA2468248C (cg-RX-API-DMAC7.html)
DK (1) DK1458399T3 (cg-RX-API-DMAC7.html)
ES (1) ES2394639T3 (cg-RX-API-DMAC7.html)
SE (1) SE0104423D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003059357A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
DK1812009T3 (da) * 2004-11-18 2013-08-05 Umecrine Ab GABA-steroidantagonister og deres anvendelse til behandling af CNS-lidelser
EP2711372A1 (en) 2006-11-21 2014-03-26 Umecrine AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
JP5687287B2 (ja) 2010-01-14 2015-03-18 ウメクライン ムード エービー 改善された保存性及び溶解特性を有する3−ベータ−ヒドロキシ−5−アルファ−プレグナン−20−オンを含有する薬学的組成物
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
RU2667065C2 (ru) 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ab公司 新穎化合物
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
US10933014B2 (en) * 2017-01-09 2021-03-02 Asarina Pharma Ab Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
CN110430883A (zh) 2017-02-10 2019-11-08 阿沙里那制药公司 用于医学治疗的3β-羟基-5α-孕烷-20-酮
CN111918657A (zh) * 2018-04-05 2020-11-10 阿沙里那制药有限公司 用于治疗物质戒断障碍的gaba-a拮抗剂
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5439900A (en) * 1993-02-25 1995-08-08 Bukusoglu; Cuneyt Methods and compositions for providing analgesia and enhanced anesthesia
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
CN1254283A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 孕烷-3-醇-20-酮
PT980381E (pt) 1997-05-02 2003-12-31 Wyeth Corp Sais farmaceuticamente aceitaveis de ester 3-sulfato de 5-alfa-pregn-16-en-3-beta-ol-20-ona com actividade de progesterona e uteis no tratamento de perturbacoes do snc
CN1254342A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 用作孕激素和治疗CNS疾病的5α-孕烷-3β,16α-二醇-20-酮3-硫酸酯的可药用盐
CN1270718C (zh) * 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
CZ20011343A3 (cs) 1998-10-13 2002-04-17 American Home Products Corporation Pregnanglukuronidy
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury

Also Published As

Publication number Publication date
ES2394639T3 (es) 2013-02-04
US8119619B2 (en) 2012-02-21
AU2009201956B2 (en) 2010-11-25
CN101601674A (zh) 2009-12-16
EP1458399A1 (en) 2004-09-22
CA2468248C (en) 2011-08-16
EP2275109A2 (en) 2011-01-19
JP2010065052A (ja) 2010-03-25
DK1458399T3 (da) 2012-11-12
JP5289281B2 (ja) 2013-09-11
US7960367B2 (en) 2011-06-14
US20110098259A1 (en) 2011-04-28
AU2009201956A1 (en) 2009-06-11
CN1607954A (zh) 2005-04-20
WO2003059357A1 (en) 2003-07-24
CN100518741C (zh) 2009-07-29
US20050222099A1 (en) 2005-10-06
JP2005519893A (ja) 2005-07-07
EP2275109A3 (en) 2011-10-12
AU2002359202B2 (en) 2009-02-19
AU2002359202C1 (en) 2011-03-31
CN101601675A (zh) 2009-12-16
AU2002359202A1 (en) 2003-07-30
EP1458399B1 (en) 2012-08-08
EP2275109B1 (en) 2013-07-24
AU2009201951A1 (en) 2009-06-04
CA2468248A1 (en) 2003-07-24
AU2009201956A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
EP2275109A3 (en) Pregnane steroids for use in the treatment of CNS disorders
TW200504078A (en) Therapeutically active compounds and their use
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2001064646A3 (en) Hydrazones and analogs as cholesterol lowering agents
TW200509937A (en) Novel compounds and their use in therapy
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
ID26781A (id) Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
DK1056856T3 (da) Modificeret ciliarneurotrofisk faktor samt fremgangsmåder til dannelse og anvendelse deraf
LU93049I2 (fr) Susoctocog
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO2004006906A3 (en) Methods for the treatment of neoplasms
BR0014312A (pt) Combinação de loteprednol e anti-histaminas
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
WO2004010936A3 (en) Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
WO2003047507A3 (en) Factor viii c2 domain variants
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
AU2002363973A8 (en) Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
BR0011250A (pt) Anticorpo monoclonal de bloqueio a vla-1 e seu uso para o tratamento de distúrbios inflamatórios
AU9157698A (en) Piperazine derivatives active on the lower urinary tract
EP1229973A4 (en) SWING FOR THE DISABLED
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
DE602004014020D1 (de) Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
BR0010560A (pt) 3-piridil-4-arilpirrois substituìdos e métodos terapêuticos e profiláticos relacionados